AGRX

Agile Therapeutics, Inc. (AGRX) | Rumor.io

Agile Therapeutics

AGRX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about AGRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 26

Agile Therapeutics, Inc. ($AGRX) has entered into a definitive merger agreement with Insud Pharma, S.L. at a price of $1.52 per share, representing a 356% premium.
The acquisition is valued at approximately $45 million, with Insud Pharma acquiring Agile Therapeutics in an all-cash deal.
The merger has led to a significant increase in Agile Therapeutics' stock price, with the company's shares trading up 332.43% following the announcement.

Generated by AI

Sentiment

Of the messages about AGRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	94.74% +36.59
Bearish	—	—	0% 0	5.26% -36.59

Bullish· Jun 26

Agile Therapeutics, Inc. (AGRX) has announced a definitive merger agreement with Insud Pharma, S.L., which is expected to bring a 356% premium to shareholders.
The merger is expected to expand Agile's significant Women's Health/contraceptive portfolio and may lead to a substantial increase in the company's value.
AGRX has already experienced a significant price increase, with a 332.43% rise, and is expected to continue growing as a result of the merger.

Bearish· Mar 25

Agile Therapeutics, Inc. (AGRX) may be delisted from the NASDAQ due to compliance concerns or low share price.
The company's share price has dropped significantly, reaching a 52-week and all-time low, and is currently trading at $0.000135.
A delisting would likely result in the company's shares being transferred to the OTC market, where they may be subject to more volatility and liquidity issues.

Generated by AI

Topics

Of the messages about AGRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	70.24%
Controversies	—	—	—	1.19%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	28.57%

Analysts· Jul 11

HC Wainwright & Co. analyst Oren Livnat maintains Agile Therapeutics (AGRX) with a Buy rating and raises the price target from $2.5 to $5.
This upgrade is expected to provide +630% upside potential for Agile Therapeutics.
Analyst Oren Livnat has a 1-star rating with an average return of -2.1% and a 41.3% success rate, according to TipRanks.com.

Announcements· Jun 26

Agile Therapeutics, Inc. (AGRX) has entered into a definitive merger agreement with Insud Pharma, S.L. to be acquired for $1.52 per share in cash.
The acquisition has a total enterprise value of approximately $45 million and is expected to expand Insud's contraceptive portfolio.
The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions, including approval by Agile's stockholders.

Technical Analysis· Jul 7

$AGRX is expected to test $0.80 again, with potential for a significant move afterwards.
The stock has formed a bull flag and is showing signs of a Cup & Handle pattern on the 1hr chart, with a falling wedge also indicating a potential upward movement.
A gap fill at $1.16 is anticipated, with a possible short squeeze occurring above $1.17, which could lead to a significant price increase.

Generated by AI

Community

Of the messages about AGRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	35.98%
Newcomers	—	—	0%	64.02%

Regulars· Jun 26

Agile Therapeutics, Inc. (AGRX) has announced a definitive merger agreement with Insud Pharma, S.L. for $1.52 per share, a 356% premium, with an expected closing in Q3 '24.
The merger will expand Agile's Women's Health/contraceptive portfolio and is expected to close with a total enterprise value of ~$45M.
Agile's merger with Insud Pharma's subsidiary, Exeltis, is a significant development for the company, with its stock price surging 325% in a single day.

Newcomers· Jun 26

Agile Therapeutics, Inc. (AGRX) has been acquired by Insud Pharma, S.L. for approximately $45 million.
The merger has led to a significant increase in AGRX's stock price, with some investors expecting it to reach $1.00 or more.
AGRX has topped the PRISM MarketView Women’s Health Index, according to market analysts, with the merger news being a major contributing factor.

Generated by AI

Also Discussed

Investors talking about AGRX also mention

#	Name	Attention
1	argenx SE American Depositary ReceiptARGX	0%0
2	VBIV - VBI Vaccines Inc.	——
3	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
4	TTNP - Titan Pharmaceuticals, Inc.	——
5	Oragenics Inc.OGEN	0%0
6	ITCI - Intra-Cellular Therapies, Inc.	——
7	United Maritime CorporationUSEA	0%0
8	ISEE - IVERIC bio, Inc.	——
9	AB Corporate Bond ETFEYEG	0%0
10	TBLT - ToughBuilt Industries, Inc.	——